Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Approval Alert | Avutometinib/Defactinib in KRAS+ Low-Grade Serous Ovarian Cancer
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the phase 2 RAMP 201 trial support the FDA approval of avutometinib plus defactinib in low-grade serous ovarian cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
2
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
3
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
4
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
5
